WS #15768
Johnson & Johnson reported a third-quarter earnings beat, with revenue of $25.4 billion and adjusted EPS of $2.59, driven by a 68% surge in Tremfya pharmaceutical sales. However, the company's medical device segment faced headwinds due to the Middle East conflict, illustrating the divergent impact of geopolitical risks across healthcare sub-sectors. This mixed result highlights the resilience of pharma demand versus the sensitivity of medical logistics to global instability.
J&J Earnings & Defense Sector Divergence
Johnson & Johnson reported a third-quarter earnings beat, with revenue of $25.4 billion and adjusted EPS of $2.59, driven by a 68% surge in Tremfya pharmaceutical sales. However, the company's medical device segment faced headwinds due to the Middle East conflict, illustrating the divergent impact of geopolitical risks across healthcare sub-sectors. This mixed result highlights the resilience of pharma demand versus the sensitivity of medical logistics to global instability.